Bluestar Adisseo Co

Chart & Performance

D1W1MN

P/E

592.77

P/S

2.35

EPS

0.02

Div Yield, %

1.70%

Shrs. gr., 5y

0.27%

Rev. gr., 5y

2.92%

Revenues

13.18b

-9.26%

Net income

52m

-95.82%

CFO

2.76b

+59.89%

Dividend

Aug 13, 20240.06 CNY/sh

Profile

Bluestar Adisseo Company engages in the research, development, production, and sale of feed additives for animal nutrition worldwide. The company's products include Rhodimet, a methionine solution for monogastric animals that is available in solid and liquid forms, such as Rhodimet NP99 and Rhodimet AT88; nutrition solutions comprising Smartamine and MetaSmart for amino acid balancing in lactating dairy cow ration formulation, as well as for dairy cows and other ruminants; and Microvit, a range of vitamins for the feed industry. It also offers Rovabio, a range of enzyme preparations that enhance the digestibility of raw materials from vegetal origin for animals, poultry, and hogs; and Selisseo 2% Se, a source of organic selenium that is based on seleno-hydroxy-methionine for use in animal feed. In addition, the company provides AdiSodium, a source of chloride-free sodium that offers a solution for dietary electrolyte balance in monogastric feeds and supplies sulphur in assimilated form to ruminant feeds; and Alterion for enhancing the animal intestinal micro ecological environment and the production performance of animal. Further, it offers PNE, a service based on NIR technology to predict the nutritional quality of the raw materials used in feed; DiM, a service and assistance program for Rhodimet AT88 applications; and E-lab, a web service that allows customers to post analytical requests and identify samples prior to shipping them to Adisseo laboratory. The company was founded in 1939 and is based in Beijing, China. Bluestar Adisseo Company is a subsidiary of China National Bluestar (Group) Co., Ltd.

URL

http://www.bluestar-adisseo.com/

IPO date

Apr 20, 2000

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	13,183,749 -9.26%	14,529,016 12.90%	12,868,681 8.05%
Cost of revenue	11,791,768	12,203,888	10,175,572
Unusual Expense (Income)
NOPBT	1,391,981	2,325,127	2,693,110
NOPBT Margin	10.56%	16.00%	20.93%
Operating Taxes	11,757	291,064	513,089
Tax Rate	0.84%	12.52%	19.05%
NOPAT	1,380,223	2,034,064	2,180,020
Net income	52,166 -95.82%	1,246,680 -15.29%	1,471,648 8.88%
Dividends	(525,354)	(477,378)	(472,015)
Dividend yield	2.45%	2.15%	1.43%
Proceeds from repurchase of equity		(1,568,817)
BB yield		7.08%
Debt
Debt current	995,400	1,138,366	918,836
Long-term debt	1,416,700	1,406,687	295,781
Deferred revenue	146,913	147,452	158,657
Other long-term liabilities	883,559	557,376	479,590
Net debt	245,209	778,003	(1,609,206)
Cash flow
Cash from operating activities	2,764,212	1,728,821	2,601,939
CAPEX	(1,447,094)	(1,542,290)	(2,313,863)
Cash from investing activities	(1,855,053)	(1,800,536)	(2,442,785)
Cash from financing activities	(797,817)	(1,163,860)	(630,677)
FCF	2,021,485	157,895	1,304,916
Balance
Cash	1,005,228	796,360	2,114,710
Long term investments	1,161,663	970,690	709,112
Excess cash	1,507,703	1,040,600	2,180,389
Stockholders' equity	13,863,866	14,952,834	14,837,155
Invested Capital	16,645,902	16,738,053	14,742,042
ROIC	8.27%	12.92%	15.25%
ROCE	7.35%	12.55%	15.31%
EV
Common stock shares outstanding	2,681,901	2,681,901	2,681,901
Price	8.00 -3.15%	8.26 -32.95%	12.32 7.04%
Market cap	21,455,210 -3.15%	22,152,505 -32.95%	33,041,024 7.04%
EV	21,728,359	22,949,753	33,435,644
EBITDA	3,117,011	3,646,530	3,871,488
EV/EBITDA	6.97	6.29	8.64
Interest	134,147	43,482	19,285
Interest/NOPBT	9.64%	1.87%	0.72%